How tech transfer timelines can make or break an oral drug launch

In this week’s Expert View, sponsored by Lonza (SWX: LONN), we look at why tech transfer is a critical yet often underestimated step in bringing oral drugs to market. As companies move from development to commercialization, even small delays or process gaps can trigger costly setbacks. We explore the challenges involved—and what leading players are doing to stay ahead.

In the high-stakes world of drug development, a pill is never just a pill. Every oral drug that reaches the market has passed through a tightly managed series of steps—none more critical, or more vulnerable, than tech transfer.

This is the point where a manufacturing process, developed in the lab or at small scale, must be reproduced consistently and reliably at commercial scale. For oral solid dosage (OSD) drugs, it’s often the final and most time-sensitive handoff before filing for approval and launching a product.

When tech transfer stumbles—or simply drags on too long—the impact can be immediate and costly.

Timelines under pressure

Tech transfer may not attract the same spotlight as clinical trials, but it plays an equally pivotal role. For companies nearing the final stage of development, the production site must be ready to prove it can consistently deliver product at scale.

Delays at this point can disrupt launch plans, postpone submissions, and complicate regulatory inspections. For early-stage or smaller players, the knock-on effects can be especially pronounced, affecting everything from funding timelines to investor confidence.

If transfer issues lead to problems like failed batches or supply interruptions, the fallout can affect not just revenue but reputation—particularly at a time when medicine shortages are under growing regulatory scrutiny.

Smooth execution is no longer just a technical achievement; it’s a signal of commercial readiness for regulators, supply chain partners, and patients alike.

OSD challenges run deep

Oral drugs are the most widely used medicines globally, yet transferring their production to a new site is rarely straightforward.

Maintaining content uniformity—especially for low-dose or potent products—can be difficult during scale-up. Small variations in processes like blending or compression can impact key product attributes. Formulations with complex release profiles or heat-sensitive ingredients introduce further challenges.

Even seemingly minor differences in manufacturing equipment between sites can affect output, requiring adjustments that can eat up time and resources. And without proper documentation and method transfer, regulatory setbacks are all but guaranteed.

What successful transfer looks like

Some in the industry are shifting how they approach tech transfer, particularly for oral drugs. That means starting earlier, aligning development and manufacturing more closely, and adopting digital tools that help predict outcomes before physical production begins.

Technologies like data modeling and digital twins are becoming more common, helping teams simulate large-scale processes and spot issues before they arise.

Coordination is also key. Successful transfers require cross-functional planning—from formulation and quality to regulatory and procurement. When these teams align early, companies are far better positioned to avoid costly surprises.

Increasingly, developers are turning to integrated outsourcing partners that handle formulation, scale-up, and production under one roof, reducing handover risks and accelerating timelines.

More than just speed

The oral drug manufacturing sector is growing rapidly, and with that growth comes intense competition—for production capacity, launch windows, and market share.

Speed now matters more than ever. But speed without control risks failure. The companies that succeed are treating tech transfer as a strategic priority—not a last-minute handoff.

They are investing in robust development, designing drugs with manufacturability in mind, and building resilience into their production platforms. Standardizing equipment, training teams to manage variability, and planning for complexity are now seen as essential.

A new commercial imperative

Tech transfer timelines have become a critical factor in the success or failure of oral drug launches. The stakes include time-to-market, supply reliability, and regulatory trust—none of which can be left to chance.

For drug developers, the message is clear: treat tech transfer as a central part of launch strategy. In an industry where timing is everything and missteps are costly, getting it right the first time is no longer optional. It’s a business imperative.

-----

White Paper: Commercial Tech Transfers in OSD Manufacturing — Lonza, a Switzerland-based CDMO, supports efficient, high-quality scale-up through structured planning and advanced manufacturing, To find our more, download the White Paper.

-----